Lifesci Capital upgraded shares of Avadel Pharmaceuticals (NASDAQ:AVDL - Free Report) to a strong-buy rating in a research note issued to investors on Wednesday morning,Zacks.com reports. Lifesci Capital also issued estimates for Avadel Pharmaceuticals' Q3 2025 earnings at $0.06 EPS, Q4 2025 earnings at $0.07 EPS, FY2025 earnings at $0.18 EPS, Q1 2026 earnings at $0.08 EPS, Q2 2026 earnings at $0.19 EPS, Q3 2026 earnings at $0.23 EPS, Q4 2026 earnings at $0.23 EPS and FY2026 earnings at $0.73 EPS.
Other equities analysts also recently issued research reports about the stock. Wells Fargo & Company began coverage on shares of Avadel Pharmaceuticals in a report on Tuesday, September 2nd. They set an "equal weight" rating and a $16.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and issued a $24.00 price target (up previously from $22.00) on shares of Avadel Pharmaceuticals in a report on Friday, August 8th. Zacks Research upgraded Avadel Pharmaceuticals to a "strong-buy" rating in a research report on Friday, August 8th. UBS Group increased their target price on Avadel Pharmaceuticals from $13.00 to $20.00 and gave the company a "buy" rating in a research report on Thursday, August 21st. Finally, Needham & Company LLC restated a "buy" rating and issued a $19.00 price objective on shares of Avadel Pharmaceuticals in a report on Thursday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Avadel Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $20.86.
Check Out Our Latest Report on AVDL
Avadel Pharmaceuticals Stock Down 2.4%
NASDAQ:AVDL traded down $0.38 during mid-day trading on Wednesday, reaching $15.38. The company's stock had a trading volume of 2,003,484 shares, compared to its average volume of 1,353,015. Avadel Pharmaceuticals has a 1 year low of $6.38 and a 1 year high of $16.66. The stock has a fifty day moving average of $12.00 and a 200-day moving average of $9.76. The firm has a market capitalization of $1.49 billion, a PE ratio of -512.67 and a beta of 1.57.
Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.08. The company had revenue of $68.13 million during the quarter, compared to analyst estimates of $60.28 million. Avadel Pharmaceuticals had a negative net margin of 1.32% and a negative return on equity of 3.73%. The firm's revenue for the quarter was up 64.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.14) earnings per share. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts expect that Avadel Pharmaceuticals will post -0.51 earnings per share for the current year.
Hedge Funds Weigh In On Avadel Pharmaceuticals
A number of hedge funds have recently modified their holdings of AVDL. BNP Paribas Financial Markets purchased a new stake in Avadel Pharmaceuticals in the 4th quarter valued at $245,000. California State Teachers Retirement System raised its position in Avadel Pharmaceuticals by 10.2% during the 4th quarter. California State Teachers Retirement System now owns 81,448 shares of the company's stock worth $856,000 after buying an additional 7,544 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Avadel Pharmaceuticals by 3.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 52,594 shares of the company's stock worth $553,000 after buying an additional 1,882 shares during the last quarter. Northern Trust Corp raised its position in Avadel Pharmaceuticals by 11.3% during the 4th quarter. Northern Trust Corp now owns 658,582 shares of the company's stock worth $6,922,000 after buying an additional 66,948 shares during the last quarter. Finally, Rhumbline Advisers raised its position in Avadel Pharmaceuticals by 2.3% during the 1st quarter. Rhumbline Advisers now owns 127,027 shares of the company's stock worth $995,000 after buying an additional 2,890 shares during the last quarter. 69.19% of the stock is currently owned by hedge funds and other institutional investors.
Avadel Pharmaceuticals Company Profile
(
Get Free Report)
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
Further Reading
Before you consider Avadel Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avadel Pharmaceuticals wasn't on the list.
While Avadel Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
